Myeloid-derived suppressor cells as a trojan horse : A cellular vehicle for the delivery of oncolytic viruses

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Pan, Ping Ying ^a   Chen, Hui ming ^a   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD16 ANTIGEN; CD32 ANTIGEN; NITRIC OXIDE; ONCOLYTIC VIRUS; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENCAPSULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; MYELOID DERIVED SSUPPRESSOR CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR PROMOTION; VESICULAR STOMATITIS VIRUS;

EID: 84885809715     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25083     Document Type: Article

References (10)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
2. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 496:445-55; PMID:23619691; http://dx.doi. org/10.1038/nature12034
3. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; PMID:18364002; http://dx.doi.org/10.1111/j.1600-065X.2008.00608.x
4. Eisenstein S, Coakley BA, Briley-Saebo K, Ma G, Meseck M, Ward S, et al. Myeloid derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res 2013; In press; PMID:23536556; http://dx.doi.org/10.1158/0008-5472.CAN-12-1597
5. Ma G, Pan PY, Eisenstein S, Divino CM, Lowell CA, Takai T, et al. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloidderived suppressor cells. Immunity 2011; 34:385-95; PMID:21376641; http://dx.doi.org/10.1016/j.immuni. 2011.02.004
6. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122:787- 95; PMID:22378047; http://dx.doi.org/10.1172/ JCI59643
7. Yang WC, Ma G, Chen SH, Pan PY. Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol 2013; 5:207-9; PMID:23532593; http:// dx.doi.org/10.1093/jmcb/mjt009
8. Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A 2012; 109:2066-71; PMID:22308357; http://dx.doi. org/10.1073/pnas.1113099109
9. Chandra D, Jahangir A, Quispe-Tintaya W, Einstein MH, Gravekamp C. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes- based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer 2013; In press; PMID:23640395; http://dx.doi.org/10.1038/ bjc.2013.206
10. Zhou Z, French DL, Ma G, Eisenstein S, Chen Y, Divino CM, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010; 28:620-32; PMID:20073041